. 2019 Oct 29;20:396. doi: 10.1186/s12882-019-1582-9

Table 2.

Changes in clinical parameters from baseline in hypoalbuminemic patients

Parameter	Baseline		SO therapy				Mean change from baseline
Parameter	−Q2	−Q1	Q1	Q2	Q3	Q4	Mean change from baseline
PB pills/d	7.9 [0.2]^a	8.9 [0.2]	3.9 [0.2]^a	4.0 [0.2]^a	4.0 [0.2]^a	4.1 [0.2]^a	−4.9 [0.5]^a
sP (mg/dL)	5.93 [0.16]^a	6.79 [0.15]	6.48 [0.15]^c	6.41 [0.15]^c	6.33 [0.15]^b	6.25 [0.15]^a	−0.40 [0.11]^c
sAlb (g/dL)	3.41 [0.03]^a	3.50 [0.03]	3.69 [0.03]^a	3.74 [0.03]^a	3.70 [0.03]^a	3.69 [0.03]^a	+ 0.18 [0.03]^a
nPCR (g/kg/d)	0.81 [0.03]^a	0.90 [0.03]	0.93 [0.02]^ns	0.93 [0.02]^ns	0.91 [0.02]^ns	0.91 [0.02]^ns	+ 0.03 [0.02]^ns
Phosphorus-attuned albumin (× 10³)	0.62 [0.01]^a	0.55 [0.01]	0.61 [0.01]^a	0.62 [0.01]^a	0.64 [0.01]^a	0.65 [0.01]^a	+ 0.08 [0.01]^a
Phosphorus-attuned nPCR (× 10³ dL/kg/d)	0.15 [0.02]^ns	0.14 [0.02]	0.15 [0.02]^c	0.15 [0.02]^c	0.16 [0.02]^b	0.16 [0.02]^a	+ 0.02 [0.01]^a
Pre-dialysis weight (kg)	89.2 [2.8]^ns	89.1 [2.8]	90.2 [2.8]^c	91.4 [2.8]^a	91.8 [2.8]^a	92.5 [2.8]^a	+ 2.2 [2.2]^a
Post-dialysis weight (kg)	86.5 [2.8]^ns	86.3 [2.8]	87.3 [2.8]^c	88.5 [2.8]^a	88.9 [2.8]^a	89.5 [2.8]^a	+ 2.1 [1.7] ^a
Equilibrated Kt/V	1.41 [0.03]^ns	1.45 [0.03]	1.49 [0.03]^ns	1.45 [0.03]^ns	1.47 [0.03]^ns	1.43 [0.03]^ns	+ 0.014 [0.02]^ns
Serum creatinine (mg/dL)	8.7 [0.4]^b	9.4 [0.4]	9.7 [0.4]^ns	10.0 [0.4]^b	10.0 [0.4]^b	9.8 [0.4]^c	+ 0.6 [0.6]^b
iPTH (pg/mL)	528 [43]^ns	568 [42]	569 [41]^ns	552 [41]^ns	579 [41]^ns	536 [41]^ns	−17 [45]^ns
Corrected calcium (mg/dL)	9.3 [0.1]^ns	9.3 [0.1]	9.3 [0.1]^ns	9.2 [0.1]^c	9.2 [0.1]^c	9.2 [0.1]^c	−0.08 [0.1]^ns

Summary statistics are expressed as LS means [standard errors]

Abbreviations: iPTH intact parathyroid hormone, LS least-square, nPCR normalized protein catabolic rate, ns non-significant, PB phosphate binder, sAlb serum albumin, SO sucroferric oxyhydroxide, sP serum phosphorus

All comparisons were carried out with −Q1 as the reference. ^aP < 0.0001, ^bP < 0.001, ^cP < 0.05, ^nsnon-significant